-77%

est. 2Y upside i

HealthcareAI & MLSeed

Rank

#903

Sector

Digital Health, Healthcare Technology Systems, Artificial Intelligence & Machine Learning

Est. Liquidity

~4Y

Data Quality

Data: Medium

StuffThatWorks presents a moderate upside opportunity driven by its strong proprietary data moat and significant potential in the high-growth AI in Clinical Trials market.

Last updated: March 10, 2026

Bull (35%)+300%

StuffThatWorks successfully leverages its proprietary 1.3 billion data points and new AI health search 'OpenStuff' to secure major B2B contracts with pharmaceutical giants, significantly accelerating clinical trials. This drives revenue to over $20M by 2028 and justifies a $160M valuation, reflecting strong market penetration and a dominant position in AI-driven RWE solutions.

Base (25%)+75%

The company continues to grow steadily, expanding its patient base and securing moderate B2B partnerships. While facing competition, its unique data moat allows for consistent revenue growth to approximately $7M-$8M by 2028, leading to a $70M valuation at a Series B or C round.

Bear (40%)-80%

Increased competition from well-funded incumbents or a slowdown in B2B adoption, coupled with the previous employee reduction, hinders growth. Revenue stagnates or declines, leading to a down round or acquisition at a significantly lower valuation of $8M, severely impacting common stock value due to liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $9M in liquidation preferences ahead of common stock, representing 22.5% of the estimated current valuation of $40M.

Dilution Risk

high

As the company has only completed a Seed round, significant dilution from future funding rounds (Series A, B, etc.) is highly probable.

Secondary Liquidity

none

Given the company's early stage, there is no active secondary market for shares or tender offers.

Questions to Ask at the Interview

Strategic questions based on StuffThatWorks's data — designed to show you've done your homework.

  • 1

    “Given the 25% reduction in employee count last year, what specific strategies are in place to stabilize and grow the team while maintaining operational efficiency and morale?”

  • 2

    “With the launch of OpenStuff and the appointment of a new CEO from a CRO background, how does StuffThatWorks plan to prioritize and balance its B2B offerings for pharmaceutical companies versus its patient-facing platform for direct engagement?”

  • 3

    “Considering the company has only raised a Seed round to date, what is the anticipated timeline for the next funding round (Series A/B), and how is the company planning to manage potential dilution for early equity holders?”

Community

Valuation Sentiment

Our model estimates -77% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.